Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial


Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability.

Download the PDF file